Reverse merger offers Yumanity faster, less risky path to NASDAQ

Despite continued demand for biotech IPOs, Yumanity has opted to take a less traditional route to the public markets in a move that it views as more efficient and less risky. 

On Monday, the company announced a reverse merger with Proteostasis Therapeutics Inc. (NASDAQ:PTI) that will result in Yumanity Therapeutics LLC listing on NASDAQ with its shareholders owning about 67.5%  of the combined entity; Proteostasis shareholders will own the remainder. ...